Medicinal composition for treating diabetes

A composition and diabetes technology, applied in drug combination, metabolic disease, pharmaceutical formula, etc., can solve the problems of usage restrictions, biguanides prone to lactic acidosis, damage to pancreatic β cells, etc., and achieve the effect of lowering blood sugar

Inactive Publication Date: 2006-02-08
SHANGHAI UNIV
View PDF0 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The treatment of type 2 diabetes mostly adopts oral hypoglycemic drug therapy. Currently, the oral hypoglycemic drugs used clinically for the treatment of type 2 diabetes include sulfonylurea hypoglycemic drugs, biguanide hypoglycemic drugs, an

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for treating diabetes
  • Medicinal composition for treating diabetes

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1: Glycosidase activity test: The proportion by weight of the pharmaceutical composition is: 51 parts of Polygonum cuspidatum extract, 24 parts of mulberry leaf extract, and 25 parts of Agrimony extract. Weigh 51 mg of Polygonum cuspidatum extract (including 1:11.73 mg of Polygonum cuspidatum extract, 2:31.62 mg of Polygonum cuspidatum extract, 3:7.65 mg of Polygonum cuspidatum extract), 24 mg of mulberry leaf extract, and 25 mg of Agrimony cuspidatum extract according to the above ratio, dissolve In 100mL water (add a small amount of dimethyl sulfoxide to aid dissolution), make a solution with a concentration of 1mg / mL. The determination method is according to the method of Tremblay et al. (Pierre C, Roland R Tremblay. The Journal of Clinicai Chemistry, 1978, 24: 208-211), that is, PNPG (4-nitrophenyl-α-D-glucopyranoside) is used as Substrate, 0.1mol / L Na 2 CO 3 As the stop solution, it was measured colorimetrically at 400nm. This composition is to the inhib...

Embodiment 2

[0027] Example 2: Detection of the inhibition of aldose reductase by the composition ratio in Example 1: Add 20 μL lithium sulfate (0.4 mol / L) to 0.86 mL phosphate buffer (pH6.5), 20 μL reduced coenzyme II (10mmol / L) solution, 10μL inhibitor solution (1mg / ml) and 60μL aldose reductase extract, incubate at 37°C for 4min, then add 30μL DL-glyceraldehyde (10mmol / L) solution, scan at 340nm Record the change in absorbance for 6 min. It is obtained through experiments that the inhibition rate of the composition on aldose reductase is 65.9%. However, the inhibition rates of aldose reductase by using three kinds of extracts alone are: Polygonum cuspidatum extract 58.2%, Mulberry leaf extract 24.1%, Agrimony extract 2.5%.

Embodiment 3

[0029]Postprandial blood glucose test: 24 normal mice (fasted for 10 hours before the experiment) were divided into 3 groups. (100mg / kg), proportioning composition in embodiment 1 and independent three kinds of extracts gavage (300mg / kg), after the end, fill starch liquid (5g / kg), then each rat is respectively in the back of filling starch liquid 0.5, 1, 2 hours to take blood. Blood glucose levels were measured at different times, and the results are shown in Table 1. figure 2 It is an effect diagram of the effect of the pharmaceutical composition on the postprandial blood glucose of mice.

[0030] physiology

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to a pharmaceutical composition for treating diabetes, wherein the constituents of the composition comprises (by weight ratio): giant knotweed rhizome extract 48-57%, mulberry leaf extract 18-25% and atrichum extract 22-33%.

Description

technical field [0001] The invention relates to a pharmaceutical composition for treating diabetes, in particular to a pharmaceutical composition using Chinese herbal medicine extracts as raw materials. Background technique [0002] Diabetes is a common chronic endocrine and metabolic disorder. Its incidence (mainly type II diabetes) is increasing year by year, and its mortality rate ranks third after tumors and cardiovascular diseases. The treatment of type 2 diabetes mostly adopts oral hypoglycemic drug therapy. Currently, the oral hypoglycemic drugs used clinically for the treatment of type 2 diabetes include sulfonylurea hypoglycemic drugs, biguanide hypoglycemic drugs, and α-glucosidase inhibitors. However, due to the strong side effects of sulfonylureas and biguanides (such as sulfonylureas damage pancreatic β cells, hypoglycemia, etc.; biguanides are prone to lactic acidosis, etc.), their use has been limited. Contents of the invention [0003] The object of the pr...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K36/73A61P3/10
Inventor 沈忠明王逸芸沈莉娟殷建伟徐正东
Owner SHANGHAI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap